These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22837135)

  • 1. Improvements in colorectal cancer screening programmes - quantitative immunochemical faecal occult blood testing - how to set the cut-off for a particular population.
    Kovarova JT; Zavoral M; Zima T; Zak A; Kocna P; Kohout P; Granatova J; Vanickova Z; Vranova J; Suchanek S; Benes Z; Celko MA; Povysil C
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):143-50. PubMed ID: 22837135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positivity rates and performances of immunochemical faecal occult blood tests at different cut-off levels within a colorectal cancer screening programme.
    Faivre J; Dancourt V; Manfredi S; Denis B; Durand G; Gendre I; Bidan JM; Jard C; Levillain R; Jung S; Viguier J; Dorval E
    Dig Liver Dis; 2012 Aug; 44(8):700-4. PubMed ID: 22542582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening.
    Raginel T; Puvinel J; Ferrand O; Bouvier V; Levillain R; Ruiz A; Lantieri O; Launoy G; Guittet L
    Gastroenterology; 2013 May; 144(5):918-25. PubMed ID: 23376426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?
    Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Niv Y
    Aliment Pharmacol Ther; 2006 Nov; 24(10):1475-81. PubMed ID: 17032281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic yield of a one sample immunochemical test at different cut-off values in an organised screening programme for colorectal cancer.
    Hamza S; Dancourt V; Lejeune C; Bidan JM; Lepage C; Faivre J
    Eur J Cancer; 2013 Aug; 49(12):2727-33. PubMed ID: 23601670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16).
    Chen LS; Liao CS; Chang SH; Lai HC; Chen TH
    J Med Screen; 2007; 14(4):191-9. PubMed ID: 18078564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An analysis of the duplicate testing strategy of an Irish immunochemical faecal occult blood test colorectal cancer screening programme.
    Kelley L; Swan N; Hughes DJ
    Colorectal Dis; 2013 Sep; 15(9):e512-21. PubMed ID: 23746062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
    de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
    Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test.
    Levi Z; Hazazi R; Rozen P; Vilkin A; Waked A; Niv Y
    Aliment Pharmacol Ther; 2006 May; 23(9):1359-64. PubMed ID: 16629942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic performance of quantitative fecal immunochemical test and multivariate prediction model for colorectal neoplasms in asymptomatic individuals.
    Omata F; Shintani A; Isozaki M; Masuda K; Fujita Y; Fukui T
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(11):1036-41. PubMed ID: 21897207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seasonal variations do not affect the superiority of fecal immunochemical tests over guaiac tests for colorectal cancer screening.
    Chausserie S; Levillain R; Puvinel J; Ferrand O; Ruiz A; Raginel T; Lantieri O; Launoy G; Guittet L
    Int J Cancer; 2015 Apr; 136(8):1827-34. PubMed ID: 25195670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population.
    Graser A; Stieber P; Nagel D; Schäfer C; Horst D; Becker CR; Nikolaou K; Lottes A; Geisbüsch S; Kramer H; Wagner AC; Diepolder H; Schirra J; Roth HJ; Seidel D; Göke B; Reiser MF; Kolligs FT
    Gut; 2009 Feb; 58(2):241-8. PubMed ID: 18852257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised comparison of two faecal immunochemical tests in population-based colorectal cancer screening.
    Grobbee EJ; van der Vlugt M; van Vuuren AJ; Stroobants AK; Mundt MW; Spijker WJ; Bongers EJC; Kuipers EJ; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E; Spaander MCW
    Gut; 2017 Nov; 66(11):1975-1982. PubMed ID: 27507905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests.
    Haug U; Hundt S; Brenner H
    Am J Gastroenterol; 2010 Mar; 105(3):682-90. PubMed ID: 19953091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use.
    Rozen P; Comaneshter D; Levi Z; Hazazi R; Vilkin A; Maoz E; Birkenfeld S; Niv Y
    Cancer; 2010 May; 116(9):2115-25. PubMed ID: 20186820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of immunochemical tests for colorectal cancer screening.
    Lejeune C; Le Gleut K; Cottet V; Galimard C; Durand G; Dancourt V; Faivre J
    Dig Liver Dis; 2014 Jan; 46(1):76-81. PubMed ID: 24012177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas.
    Khalid-de Bakker CA; Jonkers DM; Sanduleanu S; de Bruïne AP; Meijer GA; Janssen JB; van Engeland M; Stockbrügger RW; Masclee AA
    Cancer Prev Res (Phila); 2011 Oct; 4(10):1563-71. PubMed ID: 21750209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indirect comparison of two quantitative immunochemical faecal occult blood tests in a population with average colorectal cancer risk.
    Guittet L; Bailly L; Bouvier V; Launoy G
    J Med Screen; 2011; 18(2):76-81. PubMed ID: 21852699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels.
    Hol L; Wilschut JA; van Ballegooijen M; van Vuuren AJ; van der Valk H; Reijerink JC; van der Togt AC; Kuipers EJ; Habbema JD; van Leerdam ME
    Br J Cancer; 2009 Apr; 100(7):1103-10. PubMed ID: 19337257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.